Suppr超能文献

危重症患者血浆血小板活化因子乙酰水解酶活性

Plasma platelet-activating factor acetylhydrolase activity in critically ill patients.

作者信息

Claus Ralf A, Russwurm Stefan, Dohrn Barbara, Bauer Michael, Lösche Wolfgang

机构信息

Department for Anaesthesiology and Intensive Care Medicine, University Hospital Jena, Jena, Germany.

出版信息

Crit Care Med. 2005 Jun;33(6):1416-9. doi: 10.1097/01.ccm.0000165807.26485.ed.

Abstract

OBJECTIVE

Platelet-activating factor (PAF) is a potent proinflammatory mediator in systemic inflammation and sepsis and is inactivated by the enzyme PAF-acetylhydrolase (PAF-AH). Recently, a large phase III clinical trial using recombinant PAF-AH to treat patients with severe sepsis was performed but failed to reduce 28-day mortality rate. To get more information on the activity of PAF-AH in sepsis, we repeatedly measured its activity in plasma in critically ill patients compared with healthy controls.

DESIGN

Retrospective cohort study.

SETTING

Intensive care unit.

PATIENTS

Two hundred thirty-one patients who were admitted to an operative intensive care unit within 1 yr were enrolled and evaluated daily for American College of Chest Physicians/Society of Critical Care Medicine criteria. PAF-AH activity was measured as the release of [H]-acetate from [H]-acetyl-PAF.

INTERVENTIONS

Analysis of plasma samples.

MEASUREMENTS AND MAIN RESULTS

At the day of admission, PAF-AH activity of patients was below controls but markedly increased over time. Higher activities were seen in patients with severe sepsis or septic shock compared with those without organ failure. With respect to the clinical outcome, lower values were found in nonsurvivors only as long as they had not developed organ failure. In severe sepsis/septic shock, values of nonsurvivors exceeded those of survivors. PAF-AH activity was positively correlated with plasma levels of inflammatory mediators such as neopterine and tumor necrosis factor-alpha but not with acute phase reactants such as C-reactive protein, interleukin-6, or PCT. In addition, parenteral nutrition with lipid emulsions was seemingly associated with low PAF-AH activity compared with enteral nutrition.

CONCLUSION

The data indicate severity- and time-dependent changes in PAF-AH activity and may help to explain the failure of recombinant PAF-AH treatment strategies that were not based on activity measurements.

摘要

目的

血小板活化因子(PAF)是全身炎症和脓毒症中一种强效的促炎介质,可被PAF - 乙酰水解酶(PAF - AH)灭活。最近,一项使用重组PAF - AH治疗严重脓毒症患者的大型III期临床试验进行了,但未能降低28天死亡率。为了获得更多关于PAF - AH在脓毒症中活性的信息,我们将重症患者血浆中PAF - AH的活性与健康对照者进行了反复测量比较。

设计

回顾性队列研究。

地点

重症监护病房。

患者

入选了1年内入住手术重症监护病房的231例患者,并根据美国胸科医师学会/危重病医学会标准每日进行评估。PAF - AH活性通过[H] - 乙酰 - PAF释放[H] - 乙酸盐来测量。

干预措施

血浆样本分析。

测量指标及主要结果

入院当天,患者的PAF - AH活性低于对照组,但随时间显著增加。与无器官功能衰竭的患者相比,严重脓毒症或感染性休克患者的活性更高。关于临床结局,仅在未发生器官功能衰竭的非幸存者中发现较低的值。在严重脓毒症/感染性休克中,非幸存者的值超过幸存者。PAF - AH活性与新蝶呤和肿瘤坏死因子 - α等炎症介质的血浆水平呈正相关,但与C反应蛋白、白细胞介素 - 6或降钙素原等急性期反应物无关。此外,与肠内营养相比,静脉输注脂质乳剂的肠外营养似乎与低PAF - AH活性有关。

结论

数据表明PAF - AH活性存在严重程度和时间依赖性变化,这可能有助于解释未基于活性测量的重组PAF - AH治疗策略为何失败。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验